Primrose Bio

Primrose Bio is a private biotechnology firm providing innovative manufacturing solutions for the biopharmaceutical industry. Its core assets are the Pfenex platform, a high-yield prokaryotic protein expression system using Pseudomonas fluorescens, and a suite of superior RNA polymerases for mRNA synthesis. The company operates a hybrid business model, offering its platforms through feasibility programs and licensing, while also selling key reagents like the PeliCRM197® carrier protein. With six commercial product approvals leveraging its technology to date, Primrose is positioned as an enabler for developers of complex biologics and vaccines.

Pfenex Expression Technology®: A prokaryotic protein expression platform using Pseudomonas fluorescens for high-yield production of complex proteins. Prima RNApols™: Engineered RNA polymerases for high-quality, efficient mRNA synthesis.

Primrose competes in protein expression with established microbial platforms (e.g., E. coli services from Lonza, Merck) and mammalian systems (CHO cells), differentiating on its ability to produce complex proteins. In mRNA enzymes, it competes with suppliers of T7 RNA polymerase. Its PeliCRM197 competes with other CRM197 producers, but it claims a leading commercial position.